Determinants of survival after lung transplantation in telomerase-related gene mutation carriers: A retrospective cohort.


Journal

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
ISSN: 1600-6143
Titre abrégé: Am J Transplant
Pays: United States
ID NLM: 100968638

Informations de publication

Date de publication:
04 2022
Historique:
revised: 01 10 2021
received: 03 03 2021
accepted: 20 10 2021
pubmed: 3 12 2021
medline: 6 4 2022
entrez: 2 12 2021
Statut: ppublish

Résumé

Carriers of germline telomerase-related gene (TRG) mutations can show poor prognosis, with an increase in common hematological complications after lung transplantation (LT) for pulmonary fibrosis. The aim of this study was to describe the outcomes after LT in recipients carrying a germline TRG mutation and to identify the predictors of survival. In a multicenter cohort of LT patients, we retrospectively reviewed those carrying pathogenic TRG variations (n = 38; TERT, n = 23, TERC, n = 9, RTEL1, n = 6) between 2009 and 2018. The median age at LT was 54 years (interquartile range [IQR] 46-59); 68% were male and 71% had idiopathic pulmonary fibrosis. During the diagnosis of pulmonary fibrosis, 28 (74%) had a hematological disease, including eight with myelodysplasia. After a median follow-up of 26 months (IQR 15-46), 38 patients received LT. The overall post-LT median survival was 3.75 years (IQR 1.8-NA). The risk of death after LT was increased for patients with myelodysplasia (HR 4.1 [95% CI 1.5-11.5]) or short telomere (HR 2.2 [1.0-5.0]) before LT. After LT, all patients had anemia, 66% had thrombocytopenia, and 39% had neutropenia. Chronic lung allograft dysfunction frequency was 29% at 4 years. The present findings support the use of LT in TRG mutation carriers without myelodysplasia. Hematological evaluation should be systematically performed before LT.

Identifiants

pubmed: 34854205
doi: 10.1111/ajt.16893
pii: S1600-6135(22)08181-3
doi:

Substances chimiques

Telomerase EC 2.7.7.49

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

1236-1244

Informations de copyright

© 2021 The American Society of Transplantation and the American Society of Transplant Surgeons.

Références

Lederer DJ, Martinez FJ. Idiopathic pulmonary fibrosis. N Engl J Med. 2018;378(19):1811-1823. doi:10.1056/NEJMra1705751
Tsakiri KD, Cronkhite JT, Kuan PJ, et al. Adult-onset pulmonary fibrosis caused by mutations in telomerase. Proc Natl Acad Sci U S A. 2007;104(18):7552-7557. doi:10.1073/pnas.0701009104
Armanios MY, Chen J-L, Cogan JD, et al. Telomerase mutations in families with idiopathic pulmonary fibrosis. N Engl J Med. 2007;356(13):1317-1326. doi:10.1056/NEJMoa066157
Alder JK, Stanley SE, Wagner CL, Hamilton M, Hanumanthu VS, Armanios M. Exome sequencing identifies mutant TINF2 in a family with pulmonary fibrosis. Chest. 2015;147(5):1361-1368. doi:10.1378/chest.14-1947
Kropski JA, Reiss S, Markin C, et al. Rare genetic variants in PARN are associated with pulmonary fibrosis in families. Am J Respir Crit Care Med. 2017;196(11):1481-1484. doi:10.1164/rccm.201703-0635LE
Calado RT, Regal JA, Kleiner DE, et al. A spectrum of severe familial liver disorders associate with telomerase mutations. PLoS One. 2009;4(11):e7926. doi:10.1371/journal.pone.0007926
Townsley DM, Dumitriu B, Young NS. Bone marrow failure and the telomeropathies. Blood. 2014;124(18):2775-2783. doi:10.1182/blood-2014-05-526285
Popescu I, Mannem H, Winters SA, et al. Impaired CMV immunity in idiopathic pulmonary fibrosis lung transplant recipients with short telomeres. Am J Respir Crit Care Med. 2018;199(3):362-376. doi:10.1164/rccm.201805-0825OC
Borie R, Kannengiesser C, Hirschi S, et al. Severe hematologic complications after lung transplantation in patients with telomerase complex mutations. J Heart Lung Transplant. 2015;34(4):538-546. doi:10.1016/j.healun.2014.11.010
Silhan LL, Shah PD, Chambers DC, et al. Lung transplantation in telomerase mutation carriers with pulmonary fibrosis. Eur Respir J. 2014;44(1):178-187. doi:10.1183/09031936.00060014
Newton CA, Kozlitina J, Lines JR, Kaza V, Torres F, Garcia CK. Telomere length in patients with pulmonary fibrosis associated with chronic lung allograft dysfunction and post-lung transplantation survival. J Heart Lung Transpl. 2017;36(8):845-853. doi:10.1016/j.healun.2017.02.005
Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405-424. doi:10.1038/gim.2015.30
Roussel A, Sage E, Massard G, et al. Impact of donor, recipient and matching on survival after high emergency lung transplantation in France. Eur Respir J. 2019;54(5): doi:10.1183/13993003.00096-2019
Raghu G, Remy-Jardin M, Myers JL, et al. Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2018;198(5):e44-e68. doi:10.1164/rccm.201807-1255ST
Travis WD, Costabel U, Hansell DM, et al. An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013;188(6):733-748. doi:10.1164/rccm.201308-1483ST
Choi SM, O’Malley DP. Diagnostically relevant updates to the 2017 WHO classification of lymphoid neoplasms. Ann Diagn Pathol. 2018;37:67-74. doi:10.1016/j.anndiagpath.2018.09.011
Roulot D, Costes J-L, Buyck J-F, et al. Transient elastography as a screening tool for liver fibrosis and cirrhosis in a community-based population aged over 45 years. Gut. 2011;60(7):977-984. doi:10.1136/gut.2010.221382
Roden AC, Aisner DL, Allen TC, et al. Diagnosis of acute cellular rejection and antibody-mediated rejection on lung transplant biopsies: a perspective from members of the pulmonary pathology society. Arch Pathol Lab Med. 2017;141(3):437-444. doi:10.5858/arpa.2016-0459-SA
Kneidinger N, Milger K, Janitza S, et al. Lung volumes predict survival in patients with chronic lung allograft dysfunction. Eur Respir J. 2017;49(4): doi:10.1183/13993003.01315-2016
Snyder LD, Wang Z, Chen D-F, et al. Implications for human leukocyte antigen antibodies after lung transplantation. Chest. 2013;144(1):226-233. doi:10.1378/chest.12-0587
Vieri M, Kirschner M, Tometten M, et al. Comparable effects of the androgen derivatives danazol, oxymetholone and nandrolone on telomerase activity in human primary hematopoietic cells from patients with dyskeratosis congenita. Int J Mol Sci. 2020;21(19): doi:10.3390/ijms21197196
Tokman S, Singer JP, Devine MS, et al. Clinical outcomes of lung transplant recipients with telomerase mutations. J Heart Lung Transpl. 2015;34(10):1318-1324. doi:10.1016/j.healun.2015.05.002
Borie R, Tabeze L, Thabut G, et al. Prevalence and characteristics of TERT and TERC mutations in suspected genetic pulmonary fibrosis. Eur Respir J. 2016;48(6):1721-1731. doi:10.1183/13993003.02115-2015
Swaminathan AC, Neely ML, Frankel CW, et al. Lung transplant outcomes in pulmonary fibrosis patients with telomere-related gene variants. Chest. 2019;156(3):477-485. doi:10.1016/j.chest.2019.03.030
Newton CA, Batra K, Torrealba J, et al. Telomere-related lung fibrosis is diagnostically heterogeneous but uniformly progressive. Eur Respir J. 2016;48(6):1710-1720. doi:10.1183/13993003.00308-2016
Borie R, Bouvry D, Cottin V, et al. Regulator of telomere length 1 (RTEL1) mutations are associated with heterogeneous pulmonary and extra-pulmonary phenotypes. Eur Respir J. 2018;53(2):1800508. doi:10.1183/13993003.00508-2018
George G, Rosas IO, Cui YE, et al. Short telomeres, telomeropathy, and subclinical extrapulmonary organ damage in patients with interstitial lung disease. Chest. 2015;147(6):1549-1557. doi:10.1378/chest.14-0631
Schratz K, Haley L, Danoff SK, et al. Cancer spectrum and outcomes in the mendelian short telomere syndromes. Blood. 2020;135(22):1946-1956. doi:10.1182/blood.2019003264
Lata S, Marasa M, Li Y, et al. Whole-exome sequencing in adults with chronic kidney disease: a pilot study. Ann Intern Med. 2018;168(2):100-109. doi:10.7326/M17-1319

Auteurs

Mathilde Phillips-Houlbracq (M)

Service de Pneumologie A, Centre de référence des maladies pulmonaires rares (site constitutif), APHP, Hôpital Bichat, Paris, France.

Hervé Mal (H)

Université de Paris and INSERM U1152, Paris, France.
Service de Pneumologie B, APHP, Hôpital Bichat, Paris, France.

Vincent Cottin (V)

Service de Pneumologie, Centre coordonnateur national de référence des maladies pulmonaires rares, Hôpital Louis Pradel, Université Claude Bernard Lyon 1, Université de Lyon, INRAE, ERN-LUNG, Lyon, France.

Clément Gauvain (C)

Service d'oncologie, Hôpital Calmette, CHU de Lille, Lille, France.

Fabian Beier (F)

Department of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, RWTH Aachen University, Aachen, Germany.
Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), Aachen, Germany.

Flore Sicre de Fontbrune (F)

Service d'hématologie, Hôpital St Louis, APHP, Paris, France.

Sabrina Sidali (S)

Service d'hépatologie, Hôpital Beaujon, APHP, Clichy, France.

Jean François Mornex (JF)

Service de Pneumologie, Centre coordonnateur national de référence des maladies pulmonaires rares, Hôpital Louis Pradel, Université Claude Bernard Lyon 1, Université de Lyon, INRAE, ERN-LUNG, Lyon, France.

Sandrine Hirschi (S)

Service de Pneumologie, Centre de compétence des maladies pulmonaires rares, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.

Antoine Roux (A)

Service de Pneumologie, Hôpital Foch, Suresnes, France.

Gaelle Weisenburger (G)

Université de Paris and INSERM U1152, Paris, France.
Service de Pneumologie B, APHP, Hôpital Bichat, Paris, France.

Arnaud Roussel (A)

Service de chirurgie vasculaire et thoracique, Hopital Bichat, Paris, France.

Lidwine Wémeau-Stervinou (L)

Service de Pneumologie, Centre de référence des maladies pulmonaires rares (site constitutif), CHU de Lille, Lille, France.

Jérôme Le Pavec (J)

Service de Chirurgie Thoracique, Vasculaire et Transplantation Cardio-pulmonaire, Groupe Hospitalier Saint Joseph/Marie-Lannelongue, Le Plessis-Robinson, France.
Faculté de Médecine, Université Paris-Sud, Université Paris-Saclay, Le Kremlin Bicêtre, France.
UMR_S 999, Université Paris-Sud, INSERM, Hôpital Marie Lannelongue, Le Plessis Robinson, France.

Christophe Pison (C)

Service Hospitalier Universitaire Pneumologie Physiologie, Pôle Thorax et Vaisseaux, CHU Grenoble Alpes, Université Grenoble Alpes, Grenoble, France.

Sylvain Marchand Adam (S)

Service de Pneumologie, CHRU Tours, Tours, France.

Antoine Froidure (A)

Service de pneumologie, Cliniques universitaires Saint-Luc, Bruxelles, Belgique.

Romain Lazor (R)

Service de Pneumologie, Centre hospitalier universitaire vaudois, Lausanne, Suisse.

Jean-Marc Naccache (JM)

Service de Pneumologie, Centre de référence des maladies pulmonaires rares (site constitutif), Hôpital Tenon, Paris, France.

Stéphane Jouneau (S)

Service de Pneumologie, Centre de compétences des maladies rares pulmonaires, Hôpital Pontchaillou, IRSET UMR 1085, Université de Rennes 1, Rennes, France.

Hilario Nunes (H)

Service de Pneumologie Centre de référence des maladies pulmonaires rares (site constitutif), Hôpital Avicenne, Bobigny, France.

Martine Reynaud-Gaubert (M)

Service de Pneumologie, Centre de compétences des maladies pulmonaires rares, CHU Nord, AP-HM, Marseille, France.
Aix-Marseille Université, IHU Méditerranée Infection, MEPHI, Marseille, France.

Aurélie Le Borgne (A)

Service de Pneumologie, Centre de compétence des maladies pulmonaires rares Hôpital Larrey CHU Toulouse, Toulouse, France.

David Boutboul (D)

Service d'Immunopathologie Clinique, Hôpital St Louis, APHP, Paris, France.

Ibrahima Ba (I)

Laboratoire de Génétique, APHP, Hôpital Bichat, Paris, France.

Catherine Boileau (C)

Laboratoire de Génétique, APHP, Hôpital Bichat, Paris, France.

Bruno Crestani (B)

Service de Pneumologie A, Centre de référence des maladies pulmonaires rares (site constitutif), APHP, Hôpital Bichat, Paris, France.

Caroline Kannengiesser (C)

Laboratoire de Génétique, APHP, Hôpital Bichat, Paris, France.

Raphaël Borie (R)

Service de Pneumologie A, Centre de référence des maladies pulmonaires rares (site constitutif), APHP, Hôpital Bichat, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH